MatthewSaulGoldbergMD
Dermatology • New York, NYDermatopathology
Medical Director, Castle Biosciences Assistant Clinical Professor, Dermatology, The Mount Sinai Hospital
Dr. Goldberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 E 98th St
Fl 5
New York, NY 10029Phone+1 212-241-9728
Education & Training
University of Texas Southwestern Medical CenterFellowship, Dermatopathology, 2014 - 2015
University of California (San Francisco)Residency, Dermatology, 2011 - 2014
Maimonides Medical CenterInternship, Internal Medicine, 2010 - 2011
Icahn School of Medicine at Mount SinaiClass of 2010
Certifications & Licensure
AZ State Medical License 2024 - 2026
NY State Medical License 2016 - 2026
CA State Medical License 2011 - 2025
MA State Medical License 2024 - 2025
PA State Medical License 2024 - 2024
NJ State Medical License 2017 - 2021
DC State Medical License 2015 - 2018- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsObservational Study Examining the Diagnostic Practice of Ki67 Staining for Melanocytic LesionsNikki S. Vyas, Ahmad Charifa, Garrett Desman, Matthew S. Goldberg, Rajendra Singh
The American Journal of Dermatopathology. 2019-07-01 - 302 citationsThe histone variant macroH2A suppresses melanoma progression through regulation of CDK8Avnish Kapoor, Matthew S. Goldberg, Lara K. Cumberland, Kajan Ratnakumar, Miguel F. Segura
Nature. 2010-12-23 - 9 citationsMacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping.Dan Filipescu, Saul Carcamo, Aman Agarwal, Navpreet Tung, Étienne Humblin
Nature Cell Biology. 2023-09-01
Press Mentions
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant PotentialOctober 16th, 2024- Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous MedicineMarch 8th, 2023
- Data Presentation at 2023 Winter Clinical - Miamitm Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck TumorsFebruary 22nd, 2023
- Join now to see all
Professional Memberships
- Member
- American Society of DermatopathologyMember
- International Society of DermatopathologyMember
Other Languages
- Spanish, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
